Candel Therapeutics Files 8-K

TL;DR

Candel Therapeutics filed an 8-K on 4/9/24 covering Reg FD, other events, and financials.

AI Summary

Candel Therapeutics, Inc. filed an 8-K on April 9, 2024, to report on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Needham, MA.

Why It Matters

This 8-K filing provides updates on Candel Therapeutics' corporate activities and financial reporting, which are important for investors to monitor the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant negative news or events.

Key Players & Entities

• Candel Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• Needham, MA (location) — Principal Executive Offices
• April 9, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq

Filing Documents

• cadl-20240409.htm (8-K) — 46KB
• cadl-ex99_1.htm (EX-99.1) — 22KB
• img160460863_0.jpg (GRAPHIC) — 21KB
• 0000950170-24-042800.txt ( ) — 220KB
• cadl-20240409.xsd (EX-101.SCH) — 27KB
• cadl-20240409_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 9, 2024, Candel Therapeutics, Inc. (the "Company") will present a poster during the American Association for Cancer Research Annual Meeting announcing the development of a second candidate from its novel enLIGHTEN TM Discovery Platform. A copy of the full press release announcing the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

01 Other Events

Item 8.01 Other Events. On April 9, 2024, the Company announced the development of a second candidate from its novel enLIGHTEN TM Discovery Platform. The candidate is a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures ("TLS"), being developed as a novel therapeutic strategy for solid tumors. TLSs are ectopic lymphocyte aggregation structures found in the tumor microenvironment and their induction could potentially improve anti-tumor immunity. The enLIGHTEN Advanced Analytics suite was applied to immune checkpoint inhibitor-treated patient datasets, and the predicted payload components included factors regulating the development of TLS. Delivery of two unique in silico predicted payload combinations, using an enLIGHTEN programmable vector, resulted in TLS induction, monotherapy anti-tumoral activity, and enhanced responses in combination with anti-PD-1 antibody therapy in mouse models of solid tumors.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated April 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Candel Therapeutics, Inc. Date: April 9, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR